These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

60 related articles for article (PubMed ID: 10160286)

  • 1. The effect of education and drug samples on antihistamine prescribing costs in an HMO.
    Schectman JM; Schroth WS; Elinsky EG; Ott JE
    HMO Pract; 1996 Sep; 10(3):119-22. PubMed ID: 10160286
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Impact of interventions designed to increase market share and prescribing of fexofenadine at HMOs.
    Benedetto SR; Sloan AS; Duncan BS
    Am J Health Syst Pharm; 2000 Oct; 57(19):1778-85. PubMed ID: 11030030
    [TBL] [Abstract][Full Text] [Related]  

  • 3. HMO physician attitudes toward drug cost containment strategies.
    Schectman JM; Elinsky EG; Kanwal NK; Ott JE
    HMO Pract; 1995 Sep; 9(3):116-9. PubMed ID: 10151095
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The effect of an education and feedback intervention on group-model and network-model health maintenance organization physician prescribing behavior.
    Schectman JM; Kanwal NK; Schroth WS; Elinsky EG
    Med Care; 1995 Feb; 33(2):139-44. PubMed ID: 7837822
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Shifting physician prescribing to a preferred histamine-2-receptor antagonist. Effects of a multifactorial intervention in a mixed-model health maintenance organization.
    Brufsky JW; Ross-Degnan D; Calabrese D; Gao X; Soumerai SB
    Med Care; 1998 Mar; 36(3):321-32. PubMed ID: 9520957
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Counter sampling combined with medical provider education: do they alter prescribing behavior?
    Erramouspe J; Bailey JM; Cleveland KW; Casperson K; Hunt TL; Cady PS
    Consult Pharm; 2006 Aug; 21(8):636-42. PubMed ID: 17076590
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Cost savings using a stepped-care prescribing protocol for nonsteroidal anti-inflammatory drugs.
    Jones DL; Kroenke K; Landry FJ; Tomich DJ; Ferrel RJ
    JAMA; 1996 Mar; 275(12):926-30. PubMed ID: 8598620
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Electronic notifications about drug substitutes can change physician prescription habits: a cross-sectional observational study.
    Zuker A; Heart T; Parmet Y; Pliskin N; Pliskin JS
    Med Decis Making; 2011; 31(3):395-404. PubMed ID: 21127317
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The effect of an Rx-to-OTC switch on medication prescribing patterns and utilization of physician services: the case of vaginal antifungal products.
    Gurwitz JH; McLaughlin TJ; Fish LS
    Health Serv Res; 1995 Dec; 30(5):672-85. PubMed ID: 8537226
    [TBL] [Abstract][Full Text] [Related]  

  • 10. How do HMOs achieve savings? The effectiveness of one organization's strategies.
    Flood AB; Fremont AM; Jin K; Bott DM; Ding J; Parker RC
    Health Serv Res; 1998 Apr; 33(1):79-99. PubMed ID: 9566179
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Group versus individual academic detailing to improve the use of antihypertensive medications in primary care: a cluster-randomized controlled trial.
    Simon SR; Majumdar SR; Prosser LA; Salem-Schatz S; Warner C; Kleinman K; Miroshnik I; Soumerai SB
    Am J Med; 2005 May; 118(5):521-8. PubMed ID: 15866255
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Effectiveness of notification and group education in modifying prescribing of regulated analgesics.
    Anderson JF; McEwan KL; Hrudey WP
    CMAJ; 1996 Jan; 154(1):31-9. PubMed ID: 8542565
    [TBL] [Abstract][Full Text] [Related]  

  • 13. High cost HMO enrollees. Analysis of one physician's panel.
    Von Korff M; Marshall J
    HMO Pract; 1992 Mar; 6(1):20-5. PubMed ID: 10119659
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The Continuous Health Improvement Program: research in an HMO delivery system.
    Sidorov J
    HMO Pract; 1997 Jun; 11(2):97-9. PubMed ID: 10168116
    [No Abstract]   [Full Text] [Related]  

  • 15. Promotion of OTC products within a network-model HMO.
    Gilderman A; Shinmoto M; Andrews S
    Med Interface; 1996 Jun; 9(6):104-8. PubMed ID: 10157923
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Monitoring drug use in an IPA-model HMO.
    Cohen P; Jay GT
    Am J Health Syst Pharm; 1996 Jul; 53(13):1534-6. PubMed ID: 8809271
    [No Abstract]   [Full Text] [Related]  

  • 17. Evaluation and treatment of respiratory infections: does managed care make a difference?
    Hueston WJ; Mainous AG; Brauer N; Mercuri J
    J Fam Pract; 1997 Jun; 44(6):572-7. PubMed ID: 9191630
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Comparing cost effects of two quality strategies to improve test ordering in primary care: a randomized trial.
    Verstappen WH; van Merode F; Grimshaw J; Dubois WI; Grol RP; van der Weijden T
    Int J Qual Health Care; 2004 Oct; 16(5):391-8. PubMed ID: 15375100
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Perceived financial incentives, HMO market penetration, and physicians' practice styles and satisfaction.
    Hadley J; Mitchell JM; Sulmasy DP; Bloche MG
    Health Serv Res; 1999 Apr; 34(1 Pt 2):307-21. PubMed ID: 10199677
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The effect of financial and educational incentives on rational prescribing. A state-space approach.
    Pechlivanoglou P; Wieringa JE; de Jager T; Postma MJ
    Health Econ; 2015 Apr; 24(4):439-53. PubMed ID: 24519732
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 3.